“…The inclusion of monographs in the IP is based on specific criteria with priority given to drugs listed in NHPs and NLEM along with other clinically relevant drugs with significant market share. The development of monographs commences by drafting them based on validated analytical procedures and specifications approved by the regulatory authority and donated by the manufacturers to IPC ( Anonymous, 2021 , Rastogi et al, 2022 ). The drafted monographs undergo review by specialized EWGs having members from regulatory authorities, pharmaceutical industry, drug control laboratories, health authorities, and research organizations.…”